Koumpis Epameinondas, Georgoulis Vasileios, Papathanasiou Konstantina, Papoudou-Bai Alexandra, Kanavaros Panagiotis, Kolettas Evangelos, Hatzimichael Eleftheria
Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Biomedicines. 2024 Nov 21;12(12):2658. doi: 10.3390/biomedicines12122658.
Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL). Despite the use of newer agents, such as polatuzumab vedotin, more than one-third of patients have ultimately relapsed or experienced refractory disease. MiRNAs are single-stranded, ~22-nucleotide-long RNAs that interact with their target RNA. They are significant regulators of post-transcriptional gene expression. One significant miRNA, miR-155, is involved in the pathophysiology of DLBCL and it is a critical modulator of hematopoiesis, inflammation, and immune responses. Targets of miR-155, such as histone deacetylase 4 (HDAC4), suppressor of cytokine signaling-1 (SOCS1) and immune cells, play a crucial role in DLBCL pathogenesis, since miR-155 regulates key pathways, transcription factors and cytokine expression and shapes the tumor microenvironment in DLBCL. In this review, we examine the role of miR-155 in DLBCL and its potential as a future diagnostic, prognostic, or predictive biomarker.
弥漫性大B细胞淋巴瘤（DLBCL）是最常见的侵袭性非霍奇金淋巴瘤（NHL）。尽管使用了诸如泊洛妥珠单抗等新型药物，但仍有超过三分之一的患者最终复发或出现难治性疾病。微小RNA（miRNA）是单链的、长度约为22个核苷酸的RNA，可与靶RNA相互作用。它们是转录后基因表达的重要调节因子。一种重要的miRNA，即miR-155，参与了DLBCL的病理生理学过程，并且是造血、炎症和免疫反应的关键调节因子。miR-155的靶标，如组蛋白去乙酰化酶4（HDAC4）、细胞因子信号传导抑制因子1（SOCS1）和免疫细胞，在DLBCL发病机制中起关键作用，因为miR-155调节关键途径、转录因子和细胞因子表达，并塑造了DLBCL的肿瘤微环境。在本综述中，我们探讨了miR-155在DLBCL中的作用及其作为未来诊断、预后或预测生物标志物的潜力。
